Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUIDOSE: Hydroxychloroquine plus low-dose corticosteroids in pulmonary sarcoidosis
2024-516101-23-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in sarcoidosis comparing Hydroxychloroquine + low-dose corticosteroid with Low-dose corticosteroid alone (2 arms). Primary endpoint: Change in FVC % predicted from baseline to 6 months. Planned start Oct 2024; status: authorised.
02
Drugs
hydroxychloroquineprednisone
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on 2024-516101-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516101-23-00.